SEC Comment Letter 0000000000-23-007381 to Inozyme Pharma, Inc. (CIK 0001693011)
Inozyme Pharma, Inc. (CIK 0001693011)
Date: July 11, 2023 · CIK: 0001693011 · Accession: 0000000000-23-007381
AI Filing Summary & Sentiment
File numbers found in text: 001-39397
Letter
United States securities and exchange commission logo July 11, 2023 Axel Bolte President and Chief Executive Officer Inozyme Pharma, Inc. 321 Summer Street, Suite 400 Boston, MA 02210 Re:Inozyme Pharma, Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 22, 2023 File No. 001-39397 Dear Axel Bolte: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
July 11, 2023
Axel Bolte
President and Chief Executive Officer
Inozyme Pharma, Inc.
321 Summer Street, Suite 400
Boston, MA 02210
Re:Inozyme Pharma, Inc.
Form 10-K for the fiscal year ended December 31, 2022
Filed March 22, 2023
File No. 001-39397
Dear Axel Bolte:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences